The United States Potassium Clavulanate market took a small step back in November, & that decline carried over into the first week of December. Lower prices were largely due to a comfortable import availability from some of the key suppliers in India and China, plus domestic demand just wasn't all that impressive. Indian exporters did adjust their shipment schedules following some changes in their domestic pricing, which in turn freed up more supplies for the formulators here in the US. Domestic production is still limited, so the importers are basically stuck relying on those imports to get the Potassium Clavulanate to buyers for their routine prescriptions & hospital needs. Demand for Potassium Clavulanate from outpatient & hospital channels remained stable. As a result, buyers were more focused on keeping costs down & managing their stock levels, rather than rushing out to place more orders. As for early December activity, it looked like the formulators were being cautious, while the exporters were open to flexible terms to get the Potassium Clavulanate shipped out. According to market analysts, Potassium Clavulanate will likely experience further declines in pricing through mid-December, with a continued soft demand and caution exhibited by buyers at the end of the year.
